Plain-English translation of NCT07290036 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a medication called bimekizumab in adults with psoriatic arthritis or axial spondyloarthritis — two types of inflammatory joint and spine conditions. The main question is whether the medication works the same way in your body whether you receive it as an injection under your skin or through an IV (intravenous) line. The trial will help doctors understand which delivery method is best for patients.
Many people with inflammatory arthritis benefit from biologic medications, but these treatments can be given in different ways. This trial exists to prove that this medication is equally effective no matter how it's delivered, so doctors and patients can choose the method that fits best into their lives.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive the medication using one of two different delivery methods — either as an injection under your skin or through an IV line. The study has a lead-in phase where researchers will measure how the medication moves through your body, followed by a treatment period where you'll continue receiving your assigned type of medication. You'll have multiple visits so doctors can monitor your response to treatment and collect blood samples to track the medication's behavior.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States